Metastatic Breast Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (15 September 2022) | Viewed by 20306
Special Issue Editor
Special Issue Information
Dear Colleagues,
Metastatic breast cancer remains an incurable disease with a median overall survival of approximately 3 years and 5-year survival of about 25%.
In the last few years, the outcome of the MBC has changed due to new therapy options.
The most important advance in the therapy of hormone-receptor-positive, HER2-negative metastatic breast cancer was the introduction of CDK 4/6 inhibitors. The results of studies conducted in the last five years showed a substantial benefit in DFS. More recently, some studies seem to indicate an improvement in OS.
Due to the introduction of the dual blockade, as well as T-DM1 and tucatinib, the prognosis of HER2-positive MBC has changed and patients can live a long time with the disease, especially if they achieve complete remission.
Triple-negative BC (TNBC) remains the biggest “problem” within metastatic breast cancer. Some new therapies such as PARP inhibitors in patients with a germline BRCA mutation, as well as PDL-1 Inhibitors have proven to be effective for metastatic TNBC.
The determination of specific biomarkers as possible targets for therapy and determination of biomarkers that are predictive and/or prognostic factors for the outcome of breast cancer is one of the most important issues for the near future.
This Special Issue focuses on new promising therapies for metastatic breast cancer, as well as quality of life as an outcome parameter in this population.
Prof. Vesna Bjelic-Radisic
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metastatic breast cancer
- quality of life in MBC
- PARP Inhibitors
- germline BRCA mutation
- CDK 4/6 inhibitors
- breast cancer biomarkers
- immune therapy in the breast cancer